Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticolubant SCHEMBL29370595 | 1.00 | LTB4R (1.00) | LTB4R | |
| Ticolubant SCHEMBL1892766 | 1.00 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020052 | 0.95 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020057 | 0.95 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7016952 | 0.94 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020389 | 0.94 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7021487 | 0.94 | LTB4R (0.94) | LTB4R | |
| SCHEMBL7021492 | 0.94 | LTB4R (0.94) | LTB4R | |
| SCHEMBL7020038 | 0.93 | LTB4R (1.00) | LTB4R | |
| SCHEMBL7020046 | 0.93 | LTB4R (1.00) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0821673-B1 | NEW FORM OF (E)-3- 6- (2,6-DICHLOROPHENYL)-THIO]METHYL]-3-(2-PHENYLETHOXY)-2-PYRIDINYL]-2-PROPENOIC ACID | SMITHKLINE BEECHAM PLC (GB) | 2001-01-24 | — | — | EP | claimed |
| US-6093828-A | FOR TREATMENT OF PSORIASIS; RESISTANCE TO SUNLIGHT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-07-25 | — | — | US | claimed |
| EP-0821673-A1 | NEW FORM OF (E)-3- 6- (2,6-DICHLOROPHENYL)-THIO]METHYL]-3-(2-PHENYLETHOXY)-2-PYRIDINYL]-2-PROPENOIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033174-A1 | NEW FORM OF (E)-3-[6-[[(2,6-DICHLOROPHENYL)-THIO]METHYL]-3-(2-PHENYLETHOXY)-2-PYRIDINYL]-2-PROPENOIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1996-10-24 | — | — | WO | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| WO-1996026725-A1 | METHOD FOR TREATING ATOPIC DERMATITIS AND CONTACT DERMATITIS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1995015950-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | LTB4R 1206/4885 |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | LTB4R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.